The Present and Future of Inflammatory Bowel Disease Treatment.
作者信息
Sandborn William J
机构信息
Professor of Medicine and Adjunct Professor of Surgery Chief, Division of Gastroenterology Director, UCSD IBD Center University of California San Diego and UC San Diego Health System La Jolla, California.
出版信息
Gastroenterol Hepatol (N Y). 2016 Jul;12(7):438-41.
Abstract
摘要
相似文献
1
The Present and Future of Inflammatory Bowel Disease Treatment.炎症性肠病治疗的现状与未来
Gastroenterol Hepatol (N Y). 2016 Jul;12(7):438-41.
2
Genetic dissection of inflammatory bowel disease: unravelling etiology and improving diagnostics.炎症性肠病的遗传学剖析：揭示病因并改善诊断。
Expert Rev Clin Immunol. 2005 Nov;1(4):609-17. doi: 10.1586/1744666X.1.4.609.
3
Fatigue in inflammatory bowel disease.炎症性肠病中的疲劳
Tidsskr Nor Laegeforen. 2016 Nov 8;136(20):1721-1724. doi: 10.4045/tidsskr.16.0134. eCollection 2016 Nov.
4
Prospects for stem cell-based mucosal regeneration therapy in inflammatory bowel disease.基于干细胞的黏膜再生疗法在炎症性肠病中的应用前景。
Nihon Rinsho. 2017 Mar;75(3):477-481.
5
What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease?益生菌治疗炎症性肠病的证据有哪些？
J Clin Nurs. 2010 Apr;19(7-8):904-16. doi: 10.1111/j.1365-2702.2009.03123.x.
6
Age-Related Survival Differences in Patients With Inflammatory Bowel Disease-Associated Colorectal Cancer: A Population-Based Cohort Study.年龄相关性对炎症性肠病相关结直肠癌患者生存差异的影响：一项基于人群的队列研究。
Inflamm Bowel Dis. 2019 Nov 14;25(12):1957-1965. doi: 10.1093/ibd/izz088.
7
Challenges and progress in pediatric inflammatory bowel disease.小儿炎症性肠病的挑战与进展
Curr Opin Gastroenterol. 2007 Jul;23(4):406-12. doi: 10.1097/MOG.0b013e3281b115c2.
8
Malignancies in inflammatory bowel disease.
Curr Opin Gastroenterol. 2003 Jul;19(4):366-70. doi: 10.1097/00001574-200307000-00007.
9
Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition.综述文章：生物制剂在炎症性肠病治疗中不断扩大的作用——聚焦于选择性黏附分子抑制
Aliment Pharmacol Ther. 2003 Jun 15;17(12):1435-50. doi: 10.1046/j.1365-2036.2003.01603.x.
10
Pediatric inflammatory bowel disease.
Curr Opin Gastroenterol. 2004 Jul;20(4):333-40. doi: 10.1097/00001574-200407000-00006.
引用本文的文献
1
Therapeutic effect of Sheng Mai San, a traditional Chinese medicine formula, on inflammatory bowel disease via inhibition of NF-κB and NLRP3 inflammasome signaling.中药方剂生脉散通过抑制NF-κB和NLRP3炎性小体信号通路对炎症性肠病的治疗作用
Front Pharmacol. 2024 Aug 2;15:1426803. doi: 10.3389/fphar.2024.1426803. eCollection 2024.
2
Immunoglobulin A Glycosylation Differs between Crohn's Disease and Ulcerative Colitis.免疫球蛋白 A 的糖基化在克罗恩病和溃疡性结肠炎之间存在差异。
J Proteome Res. 2023 Oct 6;22(10):3213-3224. doi: 10.1021/acs.jproteome.3c00260. Epub 2023 Aug 28.
3
Therapeutic Effect of HDAC5 Binding and Cell Penetrating Peptide for the Treatment of Inflammatory Bowel Disease.HDAC5 结合细胞穿透肽治疗炎症性肠病的疗效。
Tissue Eng Regen Med. 2023 Oct;20(6):965-979. doi: 10.1007/s13770-023-00572-7. Epub 2023 Aug 17.
4
Inhibition of IRAK 1/4 alleviates colitis by inhibiting TLR4/ NF-κB pathway and protecting the intestinal barrier.抑制 IRAK1/4 通过抑制 TLR4/NF-κB 通路和保护肠道屏障来缓解结肠炎。
Bosn J Basic Med Sci. 2022 Oct 23;22(6):872-881. doi: 10.17305/bjbms.2022.7348.
5
Intraperitoneally Delivered Mesenchymal Stem Cells Alleviate Experimental Colitis Through THBS1-Mediated Induction of IL-10-Competent Regulatory B Cells.腹腔内递送间充质干细胞通过 THBS1 介导的诱导产生具有 IL-10 功能的调节性 B 细胞缓解实验性结肠炎。
Front Immunol. 2022 Mar 18;13:853894. doi: 10.3389/fimmu.2022.853894. eCollection 2022.
6
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study.维得利珠单抗治疗炎症性肠病患者的临床经验及治疗成功的预测因素：一项队列研究
BMC Gastroenterol. 2021 Jan 22;21(1):33. doi: 10.1186/s12876-021-01604-z.
7
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.维多珠单抗和抗肿瘤坏死因子α治疗在溃疡性结肠炎和克罗恩病患者中的真实世界临床疗效与安全性：一项德国回顾性病历审查
BMC Gastroenterol. 2020 Jul 8;20(1):211. doi: 10.1186/s12876-020-01332-w.
8
Phages and Their Role in Gastrointestinal Disease: Focus on Inflammatory Bowel Disease.噬菌体及其在胃肠道疾病中的作用：以炎症性肠病为重点。
Cells. 2020 Apr 18;9(4):1013. doi: 10.3390/cells9041013.
9
Baseline levels of dynamic CD4 T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study.基线水平的动态 CD4 T 细胞与 MAdCAM-1 的黏附与 vedolizumab 治疗溃疡性结肠炎的临床应答相关：一项队列研究。
BMC Gastroenterol. 2020 Apr 15;20(1):103. doi: 10.1186/s12876-020-01253-8.
10
Endoscopy in inflammatory bowel disease: from guidelines to real life.炎症性肠病中的内镜检查：从指南到现实生活
Therap Adv Gastroenterol. 2019 Jul 24;12:1756284819865153. doi: 10.1177/1756284819865153. eCollection 2019.
本文引用的文献
1
The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.治疗炎症性肠病的下一代生物制剂：来自Cochrane系统评价的证据
Inflamm Bowel Dis. 2016 Jul;22(7):1737-43. doi: 10.1097/MIB.0000000000000808.
2
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.随机临床试验：抗基质金属蛋白酶-9单克隆抗体GS-5745与安慰剂治疗溃疡性结肠炎的1期剂量范围研究。
Aliment Pharmacol Ther. 2016 Jul;44(2):157-69. doi: 10.1111/apt.13653. Epub 2016 May 24.
3
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.奥扎莫德诱导和维持治疗溃疡性结肠炎。
N Engl J Med. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248.
4
How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.未来不断发展的治疗方法和策略将如何改变我们在中度至重度活动性炎症性肠病中使用生物制剂的定位？
Inflamm Bowel Dis. 2016 Apr;22(4):998-1009. doi: 10.1097/MIB.0000000000000661.
5
Integrin-based therapeutics: biological basis, clinical use and new drugs.基于整合素的疗法：生物学基础、临床应用与新药
Nat Rev Drug Discov. 2016 Mar;15(3):173-83. doi: 10.1038/nrd.2015.10. Epub 2016 Jan 29.
6
Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.依德卢单抗[抗IP - 10]诱导治疗溃疡性结肠炎：一项随机、安慰剂对照的2b期研究。
J Crohns Colitis. 2016 Apr;10(4):418-28. doi: 10.1093/ecco-jcc/jjv224. Epub 2015 Dec 30.
Zotero 插件